C. Mullins

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

K. Davis, Y. Natkunam, M. Ozawa, 2021, Nature Medicine.

Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment

David M. Smith, C. Mullins, T. Darkow, 2014, Journal of managed care & specialty pharmacy.

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma

J. Butera, D. Treaba, A. Chorzalska, 2021, Blood Advances.

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

K. Kong, D. Miklos, C. Mackall, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

G. Salles, A. Zelenetz, A. Younes, 2020 .

Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.

S. Crosby, R. Vij, M. Tomasson, 2012, The Journal of clinical investigation.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

A. Zelenetz, A. Dogan, A. Younes, 2023, Haematologica.

Abstract 1224: A patient derived xenograft (PDX) platform for development of next generation KIT kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors (GIST)

G. Habets, Thomas B. Broudy, Cyrus Mirsaidi, 2014 .

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.

K. Davis, Y. Natkunam, M. Ozawa, 2020, Blood.

Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

Rekha R Meyer, R. Vij, S. Kulkarni, 2012, Cancer genetics.